| Description: |
Yuheng Luo,1,* Zhong Cao,2,* Pascal Geldsetzer,3 Qiushi Chen,4 Zhuang Hao,5 Liu He,6 Till Bärnighausen,2,7 Chen Wang,6,8 Simiao Chen2,6,8 1School of Health Policy and Management, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People’s Republic of China; 2Heidelberg Institute of Global Health, Faculty of Medicine and University Hospital, Heidelberg University, Heidelberg, Germany; 3Division of Primary Care and Population Health, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA; 4Harold and Inge Marcus Department of Industrial and Manufacturing Engineering, The Pennsylvania State University, University Park, PA, USA; 5School of Economics and Management, Beihang University, Beijing, People’s Republic of China; 6School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People’s Republic of China; 7Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA, USA; 8State Key Laboratory of Respiratory Health and Multimorbidity, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People’s Republic of China*These authors contributed equally to this workCorrespondence: Chen Wang, Email wangchen@pumc.edu.cn Simiao Chen, Email simiao.chen@uni-heidelberg.deBackground: Launched in 2009, China’s National Essential Public Health Services Program (NEPHSP) has been broadly implemented throughout the country. However, rigorous evaluations of its impact on chronic disease outcomes remain limited. Hypertension, being one of the major noncommunicable diseases targeted by the program, provides an important case study for assessing its effectiveness.Methods: We used longitudinal data from the China Health and Retirement Longitudinal Study (CHARLS) from 2011 to 2018 to evaluate the impact of receiving NEPHSP-covered services (from 2015 onward) on hypertension management. A difference-in-difference approach with ... |